**Table S2** - Study cohort by type of case, gender, age at BCG vaccination, time elapsed between vaccination and BCG adverse event, type BCG adverse event and time interval of isoniazid use.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Proband** | **Case** | **Gender** | **Clinical Presentation other than BCGitis** | **BCG age (d)** | **BCG-AE (d)** | **BCG-AE (type)** | **Isoniazid****(d)** | **Age at Last Assessment (y)** | **Variants in IEI-Genes** |
| 1\_1 | S | F | Only BCGitis | 214 | 31 | ISA | 174 | 5.9 | - |
| 3\_1 | S | M | Transient Infections | 9 | 242 | UL | 178 | 10.9 | LP |
| 4\_1 | S | M | Transient Infections | 6 | 80 | SL | 136 | 9.2 | VUS |
| 5\_1 | S | M | Immunoallergic Conditions | 0 | 302 | REL | 19 | 6.6 | - |
| 6\_1 | S | M | Immunoallergic Conditions | 2 | 14 | SL | 212 | 11.3 | P |
| 8\_1 | S | M | Immunoallergic Conditions | 4 | 35 | SL | 78 | 9.8 | VUS |
| 9\_1 | S | F | Only BCGitis | 1 | 232 | SL | 62 | 4.3 | VUS |
| 10\_1 | S | F | Only BCGitis | 0 | 46 | SL + ISA | 181 | 11.3 | LP |
| 11\_1 | S | M | Immunoallergic Conditions | 1 | 88 | SL | 153 | 12.1 | LP |
| 14\_1 | S | F | Immunoallergic Conditions | 3 | 181 | SL + ISA | 207 | 9.7 | P/LP |
| 15\_1 | S | M | Immunoallergic Conditions | 4 | 76 | SL | 152 | 9.2 | - |
| 16\_1 | S | F | Only BCGitis | 1 | 66 | REL | 165 | 11.6 | LP |
| 18\_1 | S | M | Only BCGitis | 9 | 66 | SL | 44 | 9.9 | LP |
| 19\_1 | S | M | Only BCGitis | 1 | 64 | SL | 127 | 9.4 | VUS |
| 20\_1 | S | F | Immunoallergic Conditions | 0 | 136 | SL | 101 | 10.2 | LP |
| 21\_1 | S | F | Immunoallergic Conditions | 1 | 15 | SL | 178 | 9.9 | P/ LP |
| 22\_1 | S | M | Transient Infections | 4 | 27 | SL + BSI | 153 | 6.2 | - |
| 25\_1 | S | F | Immunoallergic Conditions | 1 | 50 | SL | 110 | 3.9 | - |
| 26\_1 | S | M | Immunoallergic Conditions | 2 | 184 | SR | 0 | 5.8 | - |
| 27\_1 | S | M | Immunoallergic Conditions | 1 | 137 | ISA | 85 | 11.2 | LP |
| 28\_1 | S | M | Immunoallergic Conditions | 2 | 89 | SL + ISA | 62 | 4.7 | VUS |
| 29\_1 | S | F | Only BCGitis | 6 | 24 | SL | 170 | 10.6 | P |
| 32\_1 | S | M | Immunoallergic Conditions | 6 | 2 | SL + BSI | 38 | 9.7 | P |
| 33\_1 | S | M | Transient Infections | 1 | 69 | ISA | 63 | 4.8 | VUS |
| 35\_1 | S | M | Immunoallergic Conditions | 8 | 61 | SL | 201 | 8.5 | VUS |
| 36\_1 | S | F | Immunoallergic Conditions | 0 | 94 | SL | 90 | 7.0 | VUS |
| 43\_1 | S | M  | Transient Infections | 7 | 27 | GR | 89 | 0.9 | - |
| 47\_1 | S | F | Immunoallergic Conditions | 1 | 30 | SL | 61 | 5.2 | - |
| 48\_1 | S | F | Immunoallergic Conditions | 8 | 116 | ISA | 91 | 6.1 | - |
| 50\_1 | S | M | Immunoallergic Conditions | 2 | 109 | SL | 57 | 8.7 | P |
| 51\_1 | S | M | Only BCGitis | 5 | 40 | SL | 51 | 0.4 | VUS |
| 52\_1 | S | M | Only BCGitis | 6 | 120 | SL | 124 | 5.2 | - |
| 53\_1 | S | M | Only BCGitis | 6 | 92 | SL | 180 | 0.8 | - |
| 56\_1 | S | F | Only BCGitis | 3 | 98 | SL | 76 | 0.6 | VUS |
| 57\_1 | S | F | Transient Infections | 9 | 123 | SL | 150 | 7.2 | LP |
| 68\_1 | S | M | Transient Infections | 1 | 28 | SL | 249 | 3.5 | P |
| 7\_1 | FS | F | Immunoallergic Conditions | 4 | 90 | ISA | 32 | 9.8 | LP |
| 13\_1 | FS | M | Immunoallergic Conditions | 4 | 47 | SL | 90 | 9.4 | LP |
| 17\_1 | FS | M | Immunoallergic Conditions | 15 | 7 | ISA + SL | 0 | 10.7 | VUS |
| 34\_1 | FS | M | Transient Infections | 8 | 105 | ISA | 25 | 8.6 | - |
| 2\_1 | FM | M | Only BCGitis | 5 | 31 | REL | 180 | 10.8 | LP |
| 23\_1 | FM | M | Only BCGitis | 2 | 73 | SL + BSI | 118 | 11.4 | LP |
| 39\_1 | FM | M | Immunoallergic Conditions | 1 | 21 | SL | 182 | 3.9 | - |
| 44\_1 | FM | F | Immunoallergic Conditions | 11 | 60 | SL | 365 | 11.2 | - |
| Median of all cases (days) | 3.5 | 67.5 | - | 114 | 9.0 | - |
| Median of Sporadic Cases (days) | 2.5 | 72.5 | - | 117 | 7,9 | - |
| Median of Familial Cases (days) | 4.5 | 53.5 | - | 104 | 10.3 | - |

**S**=Sporadic Case. **FS**=Familial Simplex Case. **FM**= Familial Multiplex Case**. BCG-AE (days)**= Time elapsed between vaccination and adverse event to BCG, in days; **BCG-AE (type)**=Type of BCG adverse event; **ISA**=Injection site abscess; **SL**=Suppurative lymphadenitis; **UL**=Ulcer >1 cm; **REL**=Regional enlarged lymph node > 3cm; **BSI**=Bacterial Secondary infection; **GR**=Granuloma; **SR**=BCG scar Reactivation; **Isoniazid(d)**= Time interval of Isoniazid use in days. **IEI-Genes**= genes associated with Inborn Errors of Immunity by Picard *et al*.,2018. **VUS**= Variant of Uncertain Significance. **P**= Pathogenic variant. **LP**= Likely Pathogenic variant.